Progress in combination drug therapy of ulcerative colitis

doi:10.3877/cma.j.issn.1674-0785.2025.02.007

Abstract

Abstract:

Ulcerative colitis （UC） is a chronic relapsing inflammatory disease of the intestinal tract. Currently， the treatment of UC has entered the era of biologics， but there are still some patients who do not achieve complete remission. Combination therapy has been considered as a strategy to improve the therapeutic efficacy of UC. This article reviews the progress in the combination drug therapy of UC and provides a summary of combination therapy regimens to further increase the treatment options for UC patients.

Key words: Ulcerative colitis, Biological agents, Combination therapy

Shoulu Jin, Jun Liu, Yang Wu, Qian Zhou, Jie Chen. Progress in combination drug therapy of ulcerative colitis[J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(02): 145-149.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2025.02.007

https://zhlcyszz.cma-cmc.com.cn/EN/Y2025/V19/I02/145

References 39

1	Le Berre C， Honap S， Peyrin-Biroulet L. Ulcerative colitis ［J］. Lancet，2023， 402（10401）： 571-584.
2	Zhang Y， Chu X， Wang L， et al. Global patterns in the epidemiology，cancer risk， and surgical implications of inflammatory bowel disease［J］. Gastroenterol Rep （Oxf）， 2024， 12： goae053.
3	Balram B， Joshi H， Wong K， et al. Concomitant 5-aminosalicylate therapy in moderate-to-severe ulcerative colitis patients escalated to infliximab is not beneficial ［J］. Dig Dis Sci， 2021， 66（11）： 3985-3992.
4	Singh S， Proudfoot JA， Dulai PS， et al. No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy： pooled analysis of individual participant data from clinical trials ［J］. Am J Gastroenterol， 2018， 113（8）： 1197-1205.
5	Ungaro RC， Kadali H， Zhang W， et al. Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in inflammatory bowel disease： post hoc analyses of clinical trial data ［J］.J Crohns Colitis， 2023， 17（12）： 1949-1961.
6	卢佳豪，方露燕，曹曙光，等. 维得利珠单抗治疗溃疡性结肠炎的疗效及其影响因素［J］. 中华医学杂志， 2024， 104（39）： 3669-3675.
7	Nishida Y， Hosomi S， Fujimoto K， et al. Evaluating the effects of 5-aminosalicylic acid on tofacitinib treatment in ulcerative colitis ［J］. J Gastroenterol Hepatol， 2025， 40（1）： 108-114.
8	Panaccione R， Ghosh S， Middleton S， et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis ［J］. Gastroenterology， 2014， 146（2）： 392-400.e3.
9	Targownik LE， Benchimol EI， Bernstein CN， et al. Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications ［J］. J Crohns Colitis， 2020， 14（10）： 1354-1363.
10	Ito A， Omori T， Nakamura S， et al. Retrospective investigation of tacrolimus combined with an anti-tumor necrosis factorα antibody as remission induction therapy for refractory ulcerative colitis： efficacy，safety， and relapse rate ［J］. JGH Open. 2019， 3（6）： 525-531.
11	Christensen B， Gibson PR， Micic D， et al. Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease ［J］. Clin Gastroenterol Hepatol， 2019， 17（3）： 486-493.
12	Manzini R， Schwarzfischer M， Atrott K， et al. Combination of vedolizumab with tacrolimus is more efficient than vedolizumab alone in the treatment of experimental colitis ［J］. Inflamm Bowel Dis， 2021，27（12）： 1986-1998.
13	Yzet C， Diouf M， Singh S， et al. No benefit of concomitant immunomodulator therapy on eficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases： a meta-analysis ［J］. Clin Gastroenterol Hepatol， 2021， 19（4）：668-679.e8.
14	Hu A， Kotze PG， Burgevin A， et al. Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab［J］. Clin Gastroenterol Hepatol， 2021， 19（7）： 1366-1376.e2.
15	Watanabe K， Peyrin-Biroulet L， Danese S， et al. Impact of concomitant thiopurine on the efficacy and safety of filgotinib in patients with ulcerative colitis： post hoc analysis of the phase 2b/3 selection study ［J］.J Crohns Colitis， 2024， 18（6）： 801-811.
16	Liang Y， Li Y， Lee C， et al. Ulcerative colitis： molecular insights and intervention therapy ［J］. Mol Biomed， 2024， 5（1）： 42.
17	Gubatan J， Keyashian K， Rubin SJS， et al. Anti-integrins for the treatment of inflammatory bowel disease： current evidence and perspectives ［J］. Clin Exp Gastroenterol， 2021， 14： 333-342.
18	Soler D， Chapman T， Yang LL， et al. The binding specificity and selective antagonism of vedolizumab， an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases［J］. J Pharmacol Exp Ther， 2009， 330（3）： 864-875.
19	Buer LCT， Høivik ML， Warren DJ， et al. Combining anti-TNF-α and vedolizumab in the treatment of inflammatory bowel disease： a case series ［J］. Inflamm Bowel Dis， 2018， 24（5）： 997-1004.
20	Wlazlo M， Meglicka M， Wiernicka A， et al. Combination biologic therapy in pediatric inflammatory bowel disease： safety and efficacy over a minimum 12-month follow-up period ［J］. J Pediatr Gastroenterol Nutr， 2024， 79（1）： 54-61.
21	Ahmed W， Galati J， Kumar A， et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease： a systematic review and meta-analysis ［J］. Clin Gastroenterol Hepatol， 2022， 20（3）：e361-e79.
22	Verstockt B， Salas A， Sands BE， et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease ［J］. Nat Rev Gastroenterol Hepatol， 2023， 20（7）： 433-446.
23	Benson JM， Peritt D， Scallon BJ， et al. Discovery and mechanism of ustekinumab： a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders ［J］.MAbs， 2011， 3（6）： 535-45.
24	Peyrin-Biroulet L， Allegretti JR， Rubin DT， et al. Guselkumab in patients with moderately to severely active ulcerative colitis： Quasar phase 2b induction study ［J］. Gastroenterology， 2023， 165（6）： 1443-1457.
25	Feagan BG， Sands BE， Sandborn WJ， et al. VEGA study group.Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis （VEGA）：a randomised， double-blind， controlled， phase 2， proof-of-concept trial［J］. Lancet Gastroenterol Hepatol， 2023， 8（4）： 307-320.
26	Biscaglia G， Piazzolla M， Cocomazzi F， et al. Landmarks for dual biological therapy in inflammatory bowel disease： lesson from two case reports of vedolizumab in combination with ustekinumab ［J］. Eur J Gastroenterol Hepatol， 2020， 32（12）： 1579-1582.
27	Filipiuk A， Gonciarz M. Rare extraintestinal manifestations of ulcerative colitis treated with dual biologic therapy： a case report ［J］.World J Clin Cases， 2024， 12（23）： 5441-5447.
28	Chen Z， Jiang P， Su D， et al. Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease ［J］. Cytokine Growth Factor Rev， 2024， 79： 1-15.
29	Salas A， Hernandez-Rocha C， Duijvestein M， et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease ［J］.Nat Rev Gastroenterol Hepatol， 2020， 17（6）： 323-337.
30	Spalinger MR， Sayoc-Becerra A， Ordookhanian C， et al. The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions ［J］. J Crohns Colitis，2021， 15（3）： 471-484.
31	Traves PG， Murray B， Campigotto F， et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib， upadacitinib， tofacitinib and baricitinib ［J］.Ann Rheum Dis， 2021， 80（7）： 865-875.
32	Scheinberg AR， Dauer RM， Damas OM， et al. S0895 Is two better than one？ Combination therapy with vedolizumab and tofacitinib for the treatment of patients with inflammatory bowel disease ［J］. Am J Gastroenterol， 2020， 115 （1）： S460-S461.
33	Llano EM， Shrestha S， Burstein E， et al. Favorable outcomes combining vedolizumab with other biologics or tofacitinib for treatment of inflammatory bowel disease ［J］. Crohns Colitis 360， 2021，3（3）： otab030.
34	Taberner Bonastre P， Torres Vicente G， Cano-Marron M， et al.A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib ［J］. Eur J Hosp Pharm， 2021， 28（6）： 353-355.
35	Glassner K， Oglat A， Duran A， et al. The use of combination biological or small molecule therapy in inflammatory bowel disease： a retrospective cohort study ［J］. J Dig Dis， 2020， 21（5）： 264271.
36	Alayo QA， Khatiwada A， Patel A， et al. Effectiveness and safety of combining tofacitinib with a biologic in patients with refractory inflammatory bowel diseases ［J］. Inflamm Bowel Dis， 2021， 27（10）：1698-1702.
37	Lee JA， Magavi PR， Konijeti GG. Treatment of ulcerative colitis and seronegative inflammatory spondyloarthritis with vedolizumab and tofacitinib ［J］. Inflamm Bowel Dis， 2020， 26（11）： e146.
38	Le Berre C， Loeuille D， Peyrin-Biroulet L. Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy ［J］. Clin Gastroenterol Hepatol， 2019， 17（4）： 794-796.
39	Kuehbacher T， Leick A， vonGogh G， et al. Mo1906 - combination therapy of vedolizumab and tofacitinib in IBD patients with chronic active refractory disease course and spondylarthritis ［J］.Gastroenterology， 2019， 156（6）： S-881.

[1]	Weiyi Guo, Peiling Lin. Relationship between Helicobacter pylori infection with different antibody types and disease activity and histological scores in patients with ulcerative colitis [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(04): 237-244.
[2]	Hongtao Tang, Kun He. Progress and prospects of interventional therapy for advanced hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(04): 305-308.
[3]	Ying Huang, Xuan Li, Mengyang Liu, Guilin Peng, Xin Xu, Bing Wei, Chao Yang. Targeted combination therapy for advanced lung adenocarcinoma with double mutation of KRAS and BRAF genes after double lung transplantation：a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(05): 298-301.
[4]	Xiaobin Dong, Jing Zhang, Shasha Su, Hao Sheng. Differential expression profile and functional study of related circular RNA in patients with ulcerative colitis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 499-509.
[5]	Yani Li, Shuang Han, Min Chen, Junsheng Qin. Correlation of fecal bacteria with fecal calprotectin，systemic immunoinflammatory index，D-dimer level and disease severity in patients with ulcerative colitis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(02): 179-184.
[6]	Xiaolin Wang, Juan Liao, Shengrong Feng, Yi Wang, Bi Jin, Yinping Huang. Evaluation of the therapeutic effect transabdominal ultrasound submucosal index combined with blood inflammation in patients with moderate to severe ulcerative colitis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(01): 60-64.
[7]	Wei Xue, Hua Zhu, Tao Jia. Predictive value of transabdominal ultrasound submucosal index combined with hs-CRP, IL-6 and IL-8 in the early treatment of ulcerative colitis patients [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(01): 55-59.
[8]	Wenkai Sun, Qing Shen, Li Hang, Yingchun Zhang. Relationship of FAR, NAR, CRP with the evaluation and prognosis of ulcerative colitis patients [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 426-431.
[9]	Li Chen, Changqing Yang, Fengshang Zhu. Strengthen the investigation of the cross-talk mechanism between inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 385-389.
[10]	Xinyi Jiang, Dandan Gu, Yan Ye, Jiarong Miao. Study on therapeutic mechanism of antimicrobial peptides KT2 on ulcerative colitis based on RNA sequencing [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(01): 8-15.
[11]	Tao Lyu, Kun Zhang, Chen Li. Therapeutic effect of Shaohuang Anchang decoction on severe active ulcerative colitis with large intestinal dampness-heat pattern and its influence on intestinal mucosal barrier, inflammatory factors and immune function [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(01): 16-20.
[12]	Xiao Qu, Liang Wang, Ping Lu, Bin He, Min Sun. Correlation analysis of inflammatory factors in peripheral blood and characteristics of Gut microbiota with the condition of patients with active Ulcerative colitis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 466-470.
[13]	Fengshang Zhu, Ling She, Yongnian Ding, Changqing Yang. Maintaining vigilance in the differential diagnosis of inflammatory bowel disease and rare bowel disorders [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 273-276.
[14]	Liping Song, Can Zhao, Haibo Li, Xue Wang, Boyang Yao, Pingchao Xiang. Comparative analysis of FGFR tyrosine kinase inhibitors alone or in combination with chemotherapy or antiangiogenic agents in patients with EGFR-mutant NSCLC in real-world setting [J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(01): 1-7.
[15]	Jin Huang, Jing Wen, Jialin Li, Dan Han, Cuihua Liu, Dianhui Yang, Yangyang Zhang. The effect and management strategies of dual antiplatelet drugs on patients with ulcerative colitis [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2024, 11(03): 195-199.

Please choose a citation manager

Content to export